康芝药业(300086.SZ)：收到止咳橘红颗粒药物临床试验批准通知书

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of its product "Cough Orange Granules," which is already in production and sales [1] Group 1: Product Information - "Cough Orange Granules" is a product with the approval number Z10980105 and is classified as a national secondary protected traditional Chinese medicine, with its protection period ending on September 13, 2016 [1] - The current indications for the product include "clearing the lungs, stopping cough, and resolving phlegm," specifically for cough with phlegm due to phlegm-heat obstructing the lungs, characterized by excessive phlegm, chest fullness, shortness of breath, and dry throat [1] Group 2: Clinical Trial Approval - The company submitted a clinical trial application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lungs)" based on the latest clinical research and expert consensus [1] - The approval for the clinical trial signifies a potential expansion of the product's therapeutic applications [1]